Exactis is uniquely positioned to advance the development of precision cancer therapies and access to them for Canadian patients, while addressing the needs of clinical cancer researchers
Exactis is deploying Personalize my Treatment (PMT) across Canada. PMT is a unique digital cancer registry to store detailed genetic and molecular data about Canadian patients’ cancers over the duration of their cancer care that is readily accessible by academic or industry clinical researchers seeking patients with specific profiles for clinical studies.
Furthermore, Exactis provides a comprehensive range of services to facilitate initiation and conducting of clinical trials of cancer therapies, addressing the full range of needs from patient recruitment to laboratory services and administrative support. Our activities are customizable and we are open to collaborating with other clinical research organizations (CROs) in order to meet the needs of your study.
The PMT registry contains genetic and other molecular data about Canadian patients’ cancers, allowing prompt access by researchers to clinical trials for specific cohorts of patients and facilitating the conducting of clinical studies for innovative precision cancer therapies, allowing cancer patients to have earlier access to treatments that could benefit them.
The innovative Exactis research network meets a growing need of biopharmaceutical drug developers to study new precision treatments in rare populations of patients with very specific molecular profiles in their cancer, by offering study sponsors faster and simpler patient enrolment for rarer cancer populations.
We have the expertise and logistics to develop and manage biomarker-driven studies that involve serial metastatic tissue and liquid biopsy collection in patients before treatment, on-treatment and at the time of resistance. Beyond the clinical development services we offer for our clients, Exactis also develops its own trials in collaboration with academic partners (see portfolio).